LLY

1,076

-1.65%↓

JNJ

223.22

+0.45%↑

ABBV

212.61

-0.26%↓

UNH

377.52

-0.75%↓

MRK

115.8

-0.74%↓

LLY

1,076

-1.65%↓

JNJ

223.22

+0.45%↑

ABBV

212.61

-0.26%↓

UNH

377.52

-0.75%↓

MRK

115.8

-0.74%↓

LLY

1,076

-1.65%↓

JNJ

223.22

+0.45%↑

ABBV

212.61

-0.26%↓

UNH

377.52

-0.75%↓

MRK

115.8

-0.74%↓

LLY

1,076

-1.65%↓

JNJ

223.22

+0.45%↑

ABBV

212.61

-0.26%↓

UNH

377.52

-0.75%↓

MRK

115.8

-0.74%↓

LLY

1,076

-1.65%↓

JNJ

223.22

+0.45%↑

ABBV

212.61

-0.26%↓

UNH

377.52

-0.75%↓

MRK

115.8

-0.74%↓

Home・Akcijų sąrašas・Design Therapeutics Inc

Design Therapeutics Inc

Atidarymo kaina

9.94 -4.24

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

Max

10.75

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-1.6M -18M
Pelnas, tenkantis vienai akcijai	-0.29
Darbuotojai	54
EBITDA	-1.5M -20M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+87.02% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-08-05

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-115M 685M
Ankstesnė atidarymo kaina	14.18
Ankstesnė uždarymo kaina	9.94

Design Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-06-01 23:48; UTC

Rinkos pokalbiai

Nikkei May Rise on Optimism Over AI Demand -- Market Talk

2026-06-01 23:38; UTC

Įsigijimai, susijungimai, perėmimai

Google Seeks $80 Billion for AI Buildout; Berkshire Will Buy $10 Billion Stake -- WSJ

2026-06-01 23:37; UTC

Rinkos pokalbiai

Oil Edges Higher; Trump Seeks to Quell Israel-Hezbollah Conflict -- Market Talk

2026-06-01 23:01; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-06-01 23:01; UTC

Rinkos pokalbiai

Dexus Stuck in 'Too Hard' Basket -- Market Talk

2026-06-01 22:08; UTC

Įsigijimai, susijungimai, perėmimai

Alphabet to Issue $80 Billion of Equity for AI Buildout. Berkshire to Buy $10 Billion. -- Barrons.com

2026-06-01 22:01; UTC

Įsigijimai, susijungimai, perėmimai

Alphabet to Issue $80 Billion of Equity for AI Buildout. Berkshire to Buy $10 Billion. -- Barrons.com

2026-06-01 22:01; UTC

Įsigijimai, susijungimai, perėmimai

Google Seeks to Raise $80 Billion for AI Infrastructure -- Update

2026-06-01 21:55; UTC

Įsigijimai, susijungimai, perėmimai

Greg Abel's Week Is Off to Quite a Start -- WSJ

2026-06-01 21:53; UTC

Rinkos pokalbiai

Strong Earnings Suppress Concerns About Oil Market -- Market Talk

2026-06-01 21:22; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Berkshire's Abel Takes Big Swing With Back-to-Back Deals -- Market Talk

2026-06-01 20:50; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Tech, Media & Telecom Roundup: Market Talk

2026-06-01 20:50; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2026-06-01 20:50; UTC

Rinkos pokalbiai

Auto & Transport Roundup: Market Talk

2026-06-01 20:46; UTC

Įsigijimai, susijungimai, perėmimai

The Odds SpaceX Merges With Tesla Are Higher Than You Think -- Barrons.com

2026-06-01 20:22; UTC

Įsigijimai, susijungimai, perėmimai

Array Digital Infrastructure Doesn't Expect Additional Divs in 2026

2026-06-01 20:21; UTC

Įsigijimai, susijungimai, perėmimai

Array Digital Infrastructure Div Payable June 25 to Hldrs of Record June 11

2026-06-01 20:21; UTC

Įsigijimai, susijungimai, perėmimai

Array Digital Infrastructure Declares $11 Special Div

2026-06-01 20:20; UTC

Įsigijimai, susijungimai, perėmimai

Array Completes Sale of Select Spectrum Assets to Verizon for $1B

2026-06-01 19:40; UTC

Rinkos pokalbiai

Remittances to Mexico Rise for Third Straight Month -- Market Talk

2026-06-01 19:28; UTC

Rinkos pokalbiai

BoC Official Reiterates Need to Improve Business Investment -- Market Talk

2026-06-01 19:01; UTC

Rinkos pokalbiai

Oil Futures Rise On Concerns About U.S.-Iran Talks -- Market Talk

2026-06-01 18:58; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Snap 3-Session Winning Streak -- Market Talk

2026-06-01 18:54; UTC

Įsigijimai, susijungimai, perėmimai

Berkshire Stock Drops. Its Bargain-Priced Deal for Home Builder Fails to Impress Investors. -- Barrons.com

2026-06-01 18:33; UTC

Rinkos pokalbiai

Mexican PMIs Show Sluggish Manufacturing in May -- Market Talk

2026-06-01 18:32; UTC

Rinkos pokalbiai

Precious Metals Fall to Start June -- Market Talk

2026-06-01 18:00; UTC

Įsigijimai, susijungimai, perėmimai

Marsh McLennan Agency Completes Acquisition Of TriBridge Partners >MRSH

2026-06-01 17:18; UTC

Rinkos pokalbiai

Global Asset Managers Accumulate Canadian Government Debt -- Market Talk

2026-06-01 17:18; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-06-01 17:10; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Salesforce Estimated to Get $225M Sales Boost From Contentful -- Market Talk

Akcijų palyginimas

Kainos pokytis

Design Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

87.02% į viršų

12 mėnesių prognozė

Vidutinis 19.6 USD 87.02%

Aukščiausias 22 USD

Žemiausias 15 USD

Remiantis 6 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Design Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

6 ratings

Pirkti

Laikyti

Parduoti

Remiantis 6 analitikų, pateikusių Design Therapeutics Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Design Therapeutics Inc

Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.